Compare Marriott International Inc (MAR) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marriott International Inc vs McKesson Corporation — how do they compare? Marriott International Inc trades at $360.95 (market cap $92.96B), while McKesson Corporation trades at $921.5 (market cap $106.14B). The key difference: Marriott International Inc and McKesson Corporation are close in size by market cap, and Marriott International Inc pays the higher dividend (0.82%). Which is the better fit depends on your goals — on Pluang, investors hold Marriott International Inc for 164 Days and McKesson Corporation for 74 Days on average.
| MAR | MCK | |
|---|---|---|
Market Cap | $92.96B | $106.14B |
Volume | 1,173,633 | 794,405 |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $995.69 |
52-Week Low | $259.04 | $725.17 |
Typical Hold Time | 164 Days | 74 Days |
Enterprise Value | $110.28B | $112.67B |
Dividend Yield | 0.82% | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $361.08, showing minimal daily movement with a slight decline of 0.06%. The stock maintains a bullish technical signal with strong moving average support and trades near key resistance at $360. Fundamentally, the company reported solid Q2 2026 earnings beat with $3.19 EPS versus $3.08 expected, continuing revenue growth to $26.19B in 2025, though valuation ratios remain elevated with P/E at 36.9. Recent developments include new technology partnerships and upcoming dividend payment.
Marriott presents a mixed investment case with strong operational performance offset by high valuation multiples. The consensus price target of $386.71 suggests 7% upside potential, supported by 44% analyst buy ratings. Key risks include rising debt levels with debt-to-asset ratio reaching 58.83% and potential travel sector volatility. The company's dominant market position and continued travel demand provide growth catalysts, but investors should weigh valuation concerns against fundamental strength.
McKesson (MCK) trades at $930.25, up 0.93% with strong bullish momentum after recent earnings beats and positive news flow. The stock shows robust technical strength with moving averages signaling bullish alignment and price trading near resistance at $926. Fundamentally, revenue growth accelerated to $359.1 billion in 2025 with consistent profitability, though thin margins remain a characteristic of the distribution business model. Recent catalyst includes the CVS Health partnership extension through 2032, reinforcing long-term revenue visibility.
Outlook remains positive with 81% analyst buy ratings and $956.43 consensus target suggesting 2.8% upside. Key opportunities include oncology/GLP-1 growth drivers and operational efficiency gains, while risks center on drug pricing pressure, policy uncertainty, and competitive threats. The company's improved cash flow generation and debt reduction support financial stability amid sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
